Adam K. Stern is a New York based venture capitalist and private equity investment banker. He is currently a Director of LabStyle Innovations (OTCBB: DRIO), Matinas BioPharma Holdings, and is a past Director of Prolor Biotech (formerly NYSE MKT:PBTH), InVivo Therapeutics (OTC Markets:NVIV), and Organovo Holdings (NYSE MKT: ONVO). Mr. Stern is recognized in the life science community as having identified and provided the seed or early stage financing to disruptive ventures, among them the world's first 3-D bioprinter, a Time Magazine '50 Best Inventions of 2010'. Mr. Stern has rang the New York Stock Exchange opening bell with both Organovo and Prolor Biotech.
Prolor Biotech Inc. was acquired by Opko Health Inc. (OPK) in an all-stock deal valued at $480 million. In addition to providing the seed financing for Prolor, Mr. Stern, as Chairman of the Special Committee, was charged by the PROLOR Board of Directors with the responsibility to, among other things, evaluate and negotiate its eventual acquisition. Attaching Prolor Biotech's (formerly Modigene, Inc.) Carboxyl Terminal Peptide technology to therapeutic proteins is a FDA approved non-immunogenic method to substantially increase protein longevity, increasing the time between doses.
|
